Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 107

1.

Sirolimus and secondary skin-cancer prevention in kidney transplantation.

Euvrard S, Morelon E, Rostaing L, Goffin E, Brocard A, Tromme I, Broeders N, del Marmol V, Chatelet V, Dompmartin A, Kessler M, Serra AL, Hofbauer GF, Pouteil-Noble C, Campistol JM, Kanitakis J, Roux AS, Decullier E, Dantal J; TUMORAPA Study Group.

N Engl J Med. 2012 Jul 26;367(4):329-39. doi: 10.1056/NEJMoa1204166.

PMID:
22830463
[PubMed - indexed for MEDLINE]
Free Article
2.

Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus.

Bumbea V, Kamar N, Ribes D, Esposito L, Modesto A, Guitard J, Nasou G, Durand D, Rostaing L.

Nephrol Dial Transplant. 2005 Nov;20(11):2517-23. Epub 2005 Jun 28.

PMID:
15985508
[PubMed - indexed for MEDLINE]
Free Article
3.

Proteinuria following conversion from azathioprine to sirolimus in renal transplant recipients.

van den Akker JM, Wetzels JF, Hoitsma AJ.

Kidney Int. 2006 Oct;70(7):1355-7. Epub 2006 Aug 16.

PMID:
16912706
[PubMed - indexed for MEDLINE]
4.

Conversion to sirolimus for chronic allograft nephropathy and calcineurin inhibitor toxicity and the adverse effects of sirolimus after conversion.

Sayin B, Karakayali H, Colak T, Sevmis S, Pehlivan S, Demirhan B, Haberal M.

Transplant Proc. 2009 Sep;41(7):2789-93. doi: 10.1016/j.transproceed.2009.07.094.

PMID:
19765436
[PubMed - indexed for MEDLINE]
5.

Randomized controlled trial of sirolimus for renal transplant recipients at high risk for nonmelanoma skin cancer.

Campbell SB, Walker R, Tai SS, Jiang Q, Russ GR.

Am J Transplant. 2012 May;12(5):1146-56. doi: 10.1111/j.1600-6143.2012.04004.x. Epub 2012 Mar 15.

PMID:
22420843
[PubMed - indexed for MEDLINE]
Free Article
6.

Long-term results of conversion from calcineurin inhibitors to sirolimus in 150 maintenance kidney transplant patients.

Garrouste C, Kamar N, Guilbeau-Frugier C, Guitard J, Esposito L, Lavayssière L, Nogier MB, Cointault O, Ribes D, Rostaing L.

Exp Clin Transplant. 2012 Apr;10(2):110-8.

PMID:
22432753
[PubMed - indexed for MEDLINE]
Free Article
7.

Renal function improves in liver transplant recipients when switched from a calcineurin inhibitor to sirolimus.

Fairbanks KD, Eustace JA, Fine D, Thuluvath PJ.

Liver Transpl. 2003 Oct;9(10):1079-85.

PMID:
14526403
[PubMed - indexed for MEDLINE]
Free Article
8.

Proteinuria following a switch from calcineurin inhibitors to sirolimus.

Letavernier E, Pe'raldi MN, Pariente A, Morelon E, Legendre C.

Transplantation. 2005 Nov 15;80(9):1198-203.

PMID:
16314786
[PubMed - indexed for MEDLINE]
9.

Comparison of sirolimus plus tacrolimus versus sirolimus plus cyclosporine in high-risk renal allograft recipients: results from an open-label, randomized trial.

Gaber AO, Kahan BD, Van Buren C, Schulman SL, Scarola J, Neylan JF; Sirolimus High-Risk Study Group.

Transplantation. 2008 Nov 15;86(9):1187-95. doi: 10.1097/TP.0b013e318187bab0.

PMID:
19005398
[PubMed - indexed for MEDLINE]
10.

Sirolimus and skin-cancer prevention in kidney transplantation.

Smak Gregoor PJ.

N Engl J Med. 2012 Oct 18;367(16):1565; author reply 1565-6. doi: 10.1056/NEJMc1210171#SA1. No abstract available.

PMID:
23075186
[PubMed - indexed for MEDLINE]
11.

The role of sirolimus in the prevention of cutaneous squamous cell carcinoma in organ transplant recipients.

Leblanc KG Jr, Hughes MP, Sheehan DJ.

Dermatol Surg. 2011 Jun;37(6):744-9. doi: 10.1111/j.1524-4725.2011.01973..x. Review.

PMID:
21605234
[PubMed - indexed for MEDLINE]
12.

Effects of calcineurin inhibitors on sirolimus pharmacokinetics during staggered administration in renal transplant recipients.

Wu FL, Tsai MK, Chen RR, Sun SW, Huang JD, Hu RH, Chen KH, Lee PH.

Pharmacotherapy. 2005 May;25(5):646-53.

PMID:
15899725
[PubMed - indexed for MEDLINE]
13.

A retrospective study of conversion from tacrolimus-based to sirolimus-based immunosuppression in orthotopic liver transplant recipients.

Yu S, He X, Yang L, Ma Y, Zhu X, Ju W, Huang J.

Exp Clin Transplant. 2008 Jun;6(2):113-7.

PMID:
18816237
[PubMed - indexed for MEDLINE]
Free Article
14.

Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial.

Schena FP, Pascoe MD, Alberu J, del Carmen Rial M, Oberbauer R, Brennan DC, Campistol JM, Racusen L, Polinsky MS, Goldberg-Alberts R, Li H, Scarola J, Neylan JF; Sirolimus CONVERT Trial Study Group.

Transplantation. 2009 Jan 27;87(2):233-42. doi: 10.1097/TP.0b013e3181927a41.

PMID:
19155978
[PubMed - indexed for MEDLINE]
15.

Sirolimus in liver transplant recipients with renal dysfunction offers no advantage over low-dose calcineurin inhibitor regimens.

DuBay D, Smith RJ, Qiu KG, Levy GA, Lilly L, Therapondos G.

Liver Transpl. 2008 May;14(5):651-9. doi: 10.1002/lt.21429.

PMID:
18433069
[PubMed - indexed for MEDLINE]
Free Article
16.

A randomized controlled trial of late conversion from calcineurin inhibitor (CNI)-based to sirolimus-based immunosuppression in liver transplant recipients with impaired renal function.

Watson CJ, Gimson AE, Alexander GJ, Allison ME, Gibbs P, Smith JC, Palmer CR, Bradley JA.

Liver Transpl. 2007 Dec;13(12):1694-702.

PMID:
18044728
[PubMed - indexed for MEDLINE]
Free Article
17.

Two-year randomized controlled prospective trial converting treatment of stable renal transplant recipients with cutaneous invasive squamous cell carcinomas to sirolimus.

Hoogendijk-van den Akker JM, Harden PN, Hoitsma AJ, Proby CM, Wolterbeek R, Bouwes Bavinck JN, de Fijter JW.

J Clin Oncol. 2013 Apr 1;31(10):1317-23. doi: 10.1200/JCO.2012.45.6376. Epub 2013 Jan 28.

PMID:
23358973
[PubMed - indexed for MEDLINE]
Free Article
18.

Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial.

Budde K, Becker T, Arns W, Sommerer C, Reinke P, Eisenberger U, Kramer S, Fischer W, Gschaidmeier H, Pietruck F; ZEUS Study Investigators.

Lancet. 2011 Mar 5;377(9768):837-47. doi: 10.1016/S0140-6736(10)62318-5. Epub 2011 Feb 19. Erratum in: Lancet. 2012 Dec 8;380(9858):1994. Lancet. 2011 Jun 11;377(9782):2006. Wüthrich, Rudolf P [added].

PMID:
21334736
[PubMed - indexed for MEDLINE]
19.

Everolimus as primary immunosuppression in kidney transplantation: experience in conversion from calcineurin inhibitors.

Sánchez-Fructuoso AI, Ruiz JC, Calvo N, Rodrigo E, Perez-Flores I, Gómez-Alamillo C, Fernández-Pérez C, Arias M, Barrientos A.

Transplantation. 2012 Feb 27;93(4):398-405. doi: 10.1097/TP.0b013e31823ffd0e.

PMID:
22245871
[PubMed - indexed for MEDLINE]
20.

Conversion from calcineurin inhibitors to sirolimus reduces vascularization and thickness of post-transplant cutaneous squamous cell carcinomas.

Rival-Tringali AL, Euvrard S, Decullier E, Claudy A, Faure M, Kanitakis J.

Anticancer Res. 2009 Jun;29(6):1927-32.

PMID:
19528449
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk